AICAR research monograph — the AMPK activator and "exercise mimetic"
AICAR sits in research-vendor catalogues alongside the peptides, but it is not a peptide at all — it is a small-molecule nucleoside, a synthetic analogue of cellular AMP. Its entire research relevance flows from a single target: AMP-activated protein kinase (AMPK), the master energy sensor of the cell. Because switching AMPK on reproduces much of the molecular signature of physical exercise, AICAR has been labelled an "exercise mimetic" in the literature. This monograph covers what AICAR is, the AMPK mechanism that defines it, what the research record actually supports (largely preclinical), what community protocols report, and what to demand of a vendor.
Chemical identity and structure.
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside), also known as acadesine, is a nucleoside with the molecular formula C₉H₁₄N₄O₅ and a molecular weight of approximately 258.2 g/mol. It is not a peptide and has no amino-acid sequence. AICAR is a prodrug: once inside the cell it is phosphorylated by adenosine kinase to its monophosphate form, ZMP, which is the actual active species and a structural mimic of 5′-AMP.
Mechanism of action.
ZMP binds the gamma (γ) regulatory subunit of AMPK at the site normally occupied by AMP, producing allosteric activation and promoting phosphorylation of Thr172 on the α-subunit by the upstream kinases LKB1 and CaMKKβ. Activated AMPK acts as a cellular fuel gauge: it switches on catabolic, ATP-generating pathways (glucose uptake via GLUT4 translocation, fatty-acid oxidation, mitochondrial biogenesis through PGC-1α) and switches off anabolic, ATP-consuming ones. This pattern overlaps substantially with the adaptations triggered by endurance exercise, which is the basis of the "exercise mimetic" framing. AICAR is not a receptor agonist; its effects are distributed across cellular metabolism through AMPK.
Research applications and the evidence base.
AICAR is a long-standing laboratory tool for interrogating AMPK signalling. Published work spans cellular metabolism, exercise physiology, mitochondrial function, and disease modelling for type 2 diabetes, obesity, and cardiovascular disease. Oncology studies report that AICAR decreased angiogenesis and induced apoptosis in a retinoblastoma model, and pharmacology work describes Nrf2-mediated antioxidant effects and NLRP3 inflammasome inhibition in acute-pancreatitis liver injury. As acadesine, it has been studied clinically in cardiac-surgery ischaemia and in older haematology trials. Two honest caveats: most of the metabolic and "exercise-in-a-vial" claims rest on cell and animal models rather than human outcome data, and AICAR is prohibited in sport (WADA, metabolic-modulator class). It is not approved for human or veterinary use.
Community protocol information.
AICAR is sold as lyophilized powder, commonly in 50 mg vials, reconstituted with bacteriostatic water. Community protocols report subcutaneous administration, typically once daily, with conservative practice describing roughly 25 mg per day or less, cycles capped near 14 days, a washout of one to two months between cycles, and no more than a few cycles per year. These figures are summaries of community protocols circulated among researchers — they are not clinical recommendations, no confirmed human benefit has been established, and they should be read alongside the (largely preclinical) pharmacokinetic literature.
Stack combinations researchers commonly use.
In metabolic and exercise-mimetic research contexts, AICAR is most often discussed alongside other AMPK/metabolic tools — MOTS-c and SLU-PP-332 (an ERR agonist studied as a separate exercise-mimetic) — and, in body-composition research framing, alongside GLP-1 receptor agonists. The combination pharmacology here is far less characterised than the single-agent AMPK literature.
Storage and handling.
Store lyophilized AICAR frozen at −20 °C. After reconstitution, refrigerate at 2–8 °C, where it is generally reported stable for about four weeks; for longer storage, frozen aliquots at −20 °C are used. Avoid repeated freeze–thaw cycles. Add diluent slowly down the vial wall and swirl rather than shake.
Quality and COA considerations.
A meaningful COA should confirm identity by mass spectrometry (expected MW ~258 g/mol), purity by HPLC (≥98% is a reasonable benchmark for a defined small molecule), and — for any model involving injection or tissue contact — endotoxin. Because AICAR is a small molecule rather than a peptide, peptide-specific assays (e.g. sequence confirmation) do not apply; identity rests on mass and HPLC.
Research-use note: This monograph is an educational summary of the published research literature and community-reported protocols for AICAR (acadesine). AICAR is for laboratory and research use only, is not approved for human or veterinary use, is prohibited in sport, and none of the protocols described above is a therapy or a usage recommendation. Nothing here is medical advice.